OREANDA-NEWS. May 30, 2012. More than 90 leading investigators affiliated with US Oncology Research, The US Oncology Network and McKesson Specialty Health participated in over 60 studies that will be presented, displayed or published at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) held June 1 - 5 at McCormick Place in Chicago. Of those studies, 12 will be presented as oral presentations including a plenary session regarding prostate cancer co-authored by US Oncology Research affiliated physician, Nicholas Vogelzang, MD.


“The plenary session will focus on results from an exciting international Phase III clinical trial,” said Nicholas Vogelzang, MD, oncologist at Comprehensive Cancer Centers of Nevada, co-chair of the Genitourinary Committee for US Oncology Research, and the communications chair of the 2012 ASCO Annual Meeting. “This study looked at how androgen deprivation, intermittent versus continuous, affected hormone sensitive metastatic prostate cancer patients.”

“Practices and investigators affiliated with US Oncology Research continue to lead the war on cancer through development, collaboration and participation in clinical trials evaluating the latest cutting edge therapies,” said Thomas Hutson, DO, PharmD, FACP, oncologist with Texas Oncology and co-chair of the Genitourinary Committee for US Oncology Research. “With more than 60 US Oncology Research affiliated studies being featured at ASCO, this marks one of the most successful years in clinical research for us. In fact, since the mid 1990s, US Oncology Research has enrolled more than 52,000 patients into clinical trials making huge strides in the treatment of cancer across several indications.”

A part of McKesson Specialty Health, US Oncology Research enables community-based oncologists, many of whom are affiliated with The US Oncology Network, to participate in clinical research studies. US Oncology Research has a long history of bringing innovative and successful agents to market. To date, US Oncology Research has played a role in the development of 43 FDA approved cancer fighting therapies.